Screener
BioCryst Pharmaceuticals BCRX Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Finance lease liabilities | 849 | 1,441 |
| Royalty financing obligations | 382,981 | 427,233 |
| Secured term loan | 395,400 | — |
| Deferred revenue | 13,461 | — |
| Total liabilities | 1,012,140 | 633,311 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025 | 2,553 | 2,131 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's contract liabilities, non-current?
- BioCryst Pharmaceuticals (BCRX) reported contract liabilities, non-current of $13.46M in Q2 2026.
- What does contract liabilities, non-current mean?
- Obligation to transfer goods or services for which payment has been received, expected to be satisfied beyond one year.
Ask your AI about BioCryst Pharmaceuticals's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude